C2i Genomics

Whole-genome Cancer Treatment Intelligence Platform

Health Tech & Life Sciences
Acquired by Veracyte
Acquired Tirat Carmel, Israel Founded 2019
Last updated 2026-06-18
Total raised
$113.2M
Last: 2021-04
Stage
Acquired
Founded
2019
Headcount
18
HQ
Tirat Carmel, Israel
Sector
Health Tech & Life Sciences

About

C2i Genomics empowers researchers, physicians, and patients with ultra-sensitive whole-genome cancer detection. Its SaaS solution utilizes a cloud-based platform to perform cancer tumor burden monitoring on a global scale, leveraging the thousands of already installed genome sequencers around the world. Using scientific breakthroughs, growing genomic and clinical databases, and sophisticated signal processing and artificial intelligence, C2i enables high-precision personalized medicine, reduced cancer treatment costs, and accelerated drug development.

C2i Genomics provides acuity in cancer detection and monitoring by combining whole genome sequencing with a proprietary AI-based tumor enrichment method that recognizes patient-specific cancer patterns.

Funding history · 3 rounds · $113.2M total

Q&A

What is C2i Genomics' primary focus?
C2i Genomics focuses on providing a whole-genome cancer treatment intelligence platform that empowers researchers, physicians, and patients with ultra-sensitive whole-genome cancer detection.
When was C2i Genomics founded?
C2i Genomics was founded in August 2019.
What is C2i Genomics' employee count?
C2i Genomics has 11-50 employees.
What is the total amount of funding C2i Genomics has raised?
C2i Genomics has raised a total of $113,200,000 USD.
Which investors participated in C2i Genomics' April 2021 funding round?
In April 2021, C2i Genomics raised $100,000,000 USD in a round led by.
What is C2i Genomics' current status?
C2i Genomics was acquired by Veracyte in January 2024.
Where is C2i Genomics headquartered?
C2i Genomics is headquartered in Tirat Carmel, Israel.
What technologies does C2i Genomics utilize?
C2i Genomics utilizes platforms & interfaces, software, data storage, cloud, artificial intelligence, and machine learning.

Team · 3

Founder · Co-founder, CEO & CSO
LinkedIn ↗
Founder · Co-founder & CTO
LinkedIn ↗
Founder · Co-founder, General Manager and CFO
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesDigital HealthcareDigital Medical Diagnostics
Technologies
Platforms & InterfacesSoftwareData StorageCloudArtificial IntelligenceMachine Learning
Target customers
Healthcare & Life SciencesHealthcareProvidersInsurance CompaniesLife SciencesPharmaceuticals
Business model
B2B

Highlights

1 PatentsVerified

Tags

saasgenomicsreal-timeearly-detectioncancerbioinformaticsdigital-healthcareinsurance-companiesoncologymonitoringdoctorsdiagnosticsblood-testbiopsyartificial-intelligencehealthcare-providerspersonalizationpharma-companiesdata-analyticscloud-basedmachine-learningclinical-trials
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websiteveracyte.com/mrd-technology
LinkedInlinkedin.com/company/36105135

Identifiers & details

Founded2019-8
Employees (exact)18
OfficesNew York; Cambridge
Status reasonAcquired by Veracyte on Jan, 2024

Acquisitions & public offerings

Acquired by Veracyte 2024-01

Radar intelligence

Web history (Wayback)

Domainveracyte.com